PCMA Statement on New Class-Action Lawsuit Against Drug Companies

WASHINGTON, Jan. 30, 2017 /PRNewswire-USNewswire/ -- The Pharmaceutical Care Management Association (PCMA) issued the following statement on today's new class-action lawsuit against three makers of insulin drug products:

"While we're still reviewing the details of the lawsuit – in which pharmacy benefit managers (PBMs) are not named as defendants – it inexplicably attacks prescription drug rebates, long used to reduce costs in public programs like Medicaid and in the commercial market. 

While none of America's largest, most sophisticated health purchasers – including Fortune 500 companies, health plans, and Medicare Part D plans – are required to use the services of a PBM, almost all choose to because they reduce costs and improve the quality of benefits."

PCMA is the national association representing America's pharmacy benefit managers (PBMs). PBMs administer prescription drug plans for more than 266 million Americans who have health insurance from a variety of sponsors including: commercial health plans, self-insured employer plans, union plans, Medicare Part D plans, the Federal Employees Health Benefits Program (FEHBP), state government employee plans, managed Medicaid plans, and others.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pcma-statement-on-new-class-action-lawsuit-against-drug-companies-300399022.html

SOURCE Pharmaceutical Care Management Association